Candriam Luxembourg S.C.A. maintained its position in shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) during the second quarter, Holdings Channel reports. The firm owned 201,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Tetraphase Pharmaceuticals were worth $1,433,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Wade G W & Inc. bought a new position in shares of Tetraphase Pharmaceuticals during the first quarter valued at approximately $138,000. Teza Capital Management LLC boosted its position in shares of Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,281 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,496 shares during the last quarter. UBS Group AG boosted its position in shares of Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 387 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Tetraphase Pharmaceuticals during the first quarter valued at approximately $181,000. 35.76% of the stock is currently owned by institutional investors and hedge funds.

Tetraphase Pharmaceuticals, Inc. (NASDAQ TTPH) opened at 5.35 on Friday. The company’s market cap is $273.13 million. The firm has a 50-day moving average of $6.97 and a 200-day moving average of $6.94. Tetraphase Pharmaceuticals, Inc. has a one year low of $3.11 and a one year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.07. The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.47) EPS. On average, analysts predict that Tetraphase Pharmaceuticals, Inc. will post ($2.55) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Tetraphase Pharmaceuticals, Inc. (TTPH) Stake Maintained by Candriam Luxembourg S.C.A.” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/12/tetraphase-pharmaceuticals-inc-ttph-stake-maintained-by-candriam-luxembourg-s-c-a.html.

Several brokerages have recently commented on TTPH. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research report on Wednesday. BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. BMO Capital Markets reissued an “outperform” rating and issued a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Finally, Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $10.65.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Want to see what other hedge funds are holding TTPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH).

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.